# OnCo record her2climb-05 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/her2climb-05/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "her2climb-05", "NCT05132582" ;
  schema:name "HER2CLIMB-05"@en ;
  schema:description "In HER2CLIMB-05, adding the brain-penetrant pill tucatinib to maintenance antibodies after first-line chemotherapy delayed progression by more than eight months."@en ;
  schema:url <https://onco.cc/trials/her2climb-05/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05132582>, <https://ascopubs.org/doi/10.1200/JCO-25-02600> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2022-03-07" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-breast-brain-metastases/> ;
  onco:technologies <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-her2climb-05-j-clin-oncol-2026/> .